Gross Margin ExpansionA large jump in gross margin suggests meaningful improvement in cost of goods sold or pricing power, which enhances long-term profitability potential. Sustained higher gross margins provide a structural cushion to absorb R&D and SG&A, improving chances to fund growth without continual capital raises.

Return To ProfitabilityRe-establishing net income indicates the business can achieve positive operating economics after prior losses. If this reflects structural cost discipline or improved product mix, it supports sustainable earnings generation and greater internal funding capacity for clinical programs and commercialization over the medium term.

Specialized Regenerative-medicine FocusA focused product set in regenerative medicine aligns with high barriers to entry, specialized know-how, and potential for licensing/partnership revenues. Core competencies in cellular therapies and biomaterials support long-term competitive differentiation and multiple commercial and institutional revenue channels.

Bears Say

High LeverageElevated leverage materially reduces financial flexibility and increases interest and refinancing risk, particularly for a biotech that may require sustained R&D and commercialization spend. High debt amplifies downside in revenue shortfalls and can constrain strategic options over the medium term.

Zero Operating/free Cash FlowAbsent operating and free cash flow undermines the firm’s ability to self-fund clinical development, manufacturing scale-up, or market expansion. Reliance on external financing raises dilution or debt risks and limits capacity to capitalize on commercial opportunities or absorb regulatory and development setbacks.

Volatile Revenue And Small ScaleInconsistent revenue trends and a very small employee base suggest limited commercial scale and execution bandwidth. Revenue volatility complicates forecasting and investment planning, while constrained human resources may slow product launches, partnerships, and broader market penetration over the next several months.

8158 FAQ

What was China Regenerative Medicine International Limited’s price range in the past 12 months?

China Regenerative Medicine International Limited lowest stock price was HK$0.24 and its highest was HK$1.20 in the past 12 months.

What is China Regenerative Medicine International Limited’s market cap?

China Regenerative Medicine International Limited’s market cap is HK$109.53M.

When is China Regenerative Medicine International Limited’s upcoming earnings report date?

China Regenerative Medicine International Limited’s upcoming earnings report date is Mar 26, 2026 which is in 29 days.

How were China Regenerative Medicine International Limited’s earnings last quarter?

Currently, no data Available

Is China Regenerative Medicine International Limited overvalued?

According to Wall Street analysts China Regenerative Medicine International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does China Regenerative Medicine International Limited pay dividends?

China Regenerative Medicine International Limited does not currently pay dividends.

What is China Regenerative Medicine International Limited’s EPS estimate?

China Regenerative Medicine International Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Regenerative Medicine International Limited have?

China Regenerative Medicine International Limited has 304,252,470 shares outstanding.

What happened to China Regenerative Medicine International Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of China Regenerative Medicine International Limited?

Currently, no hedge funds are holding shares in HK:8158

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

China Regenerative Medicine International Limited

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.